| Literature DB >> 31386593 |
Rosina Pryor1,2, Daniel Martinez-Martinez1,2, Leonor Quintaneiro1,2,3, Filipe Cabreiro1,2.
Abstract
The microbiome is known to regulate many aspects of host health and disease and is increasingly being recognized as a key mediator of drug action. However, investigating the complex multidirectional relationships between drugs, the microbiota, and the host is a challenging endeavor, and the biological mechanisms that underpin these interactions are often not well understood. In this review, we outline the current evidence that supports a role for the microbiota as a contributor to both the therapeutic benefits and side effects of drugs, with a particular focus on those used to treat mental disorders, type 2 diabetes, and cancer. We also provide a snapshot of the experimental and computational tools that are currently available for the dissection of drug-microbiota-host interactions. The advancement of knowledge in this area may ultimately pave the way for the development of novel microbiota-based strategies that can be used to improve treatment outcomes.Entities:
Keywords: antipsychotics; cancer; drugs; metabolism; metformin; microbiome
Mesh:
Year: 2019 PMID: 31386593 DOI: 10.1146/annurev-pharmtox-010919-023612
Source DB: PubMed Journal: Annu Rev Pharmacol Toxicol ISSN: 0362-1642 Impact factor: 13.820